Capromab pendetide
Identification
- Name
- Capromab pendetide
- Accession Number
- DB00089 (BTD00080, BIOD00080)
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Description
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.
- Protein structure
- Protein chemical formula
- Not Available
- Protein average weight
- Not Available
- Sequences
- Not Available
- Synonyms
- (111In)-Capromab pendetide
- Indium (111In) capromab pendetide
- Indium 111 Capromab Pendetide
- Indium In 111 capromab pendetide
- External IDs
- CYT-356 / Cytogen 356
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataProstaScint Kit for the Preparation of Indium In 111 Capromab Pendetide Kit 0.5 mg/1mL Intravenous Jazz Pharmaceuticals 1996-10-28 Not applicable US 
Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- International/Other Brands
- ProstaScint (Cytogen Corp.)
- Categories
- Amino Acids, Peptides, and Proteins
- Antibodies
- Blood Proteins
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Globulins
- Immunoglobulins
- Immunoproteins
- Indicators and Reagents
- Indium (111In) Compounds
- Indium Radioisotopes
- Laboratory Chemicals
- Prostatic Neoplasms
- Proteins
- Serum Globulins
- Tumour Detection
- UNII
- BDO5072GRX
- CAS number
- 145464-28-4
Pharmacology
- Indication
For diagnosis of prostate cancer and detection of intra-pelvic metastases.
- Associated Conditions
- Pharmacodynamics
Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
- Mechanism of action
Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Target Actions Organism AGlutamate carboxypeptidase 2 other/unknownHumans - Absorption
- Not Available
- Volume of distribution
- 4 ± 2.1 L
- Protein binding
- Not Available
- Metabolism
Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production
- Route of elimination
Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
- Half life
- Not Available
- Clearance
- 42 +/- 22 mL/hr
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn moreStructured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn moreStructured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide. Abituzumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abituzumab. Abrilumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abrilumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide. Adecatumumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Adecatumumab. Aducanumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab. Afelimomab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Afelimomab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide. Alirocumab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab. Amatuximab The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amatuximab. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- General References
- External Links
- PubChem Substance
- 46506263
- RxNav
- 136300
- ChEMBL
- CHEMBL2108285
- Therapeutic Targets Database
- DAP001049
- PharmGKB
- PA164745489
- Wikipedia
- Indium_(111In)_capromab_pendetide
- ATC Codes
- V09IB04 — Indium (111in) capromab pendetide
- FDA label
- Download (1.65 MB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Diagnostic Prostate Cancer 1 2 Completed Diagnostic Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- EUSA Pharma Inc.
- Dosage forms
Form Route Strength Kit Intravenous 0.5 mg/1mL - Prices
Unit description Cost Unit Prostascint kit 1584.0USD kit DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 61 °C (FAB fragment), 71 °C (whole mAb) Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
Taxonomy
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Other/unknown
- General Function
- Tetrahydrofolyl-poly(glutamate) polymer binding
- Specific Function
- Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
- Gene Name
- FOLH1
- Uniprot ID
- Q04609
- Uniprot Name
- Glutamate carboxypeptidase 2
- Molecular Weight
- 84330.015 Da
References
- Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653]
- Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479]
- Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077]
- Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Drug created on June 13, 2005 07:24 / Updated on May 02, 2020 03:11
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","FC-All.jpg":"/assets/ads/FC-All-1b11d152f78f0d480e56661324a86c44bcb958ce82c6ae516565e718ae8c1968.jpg","FC-3.jpg":"/assets/ads/FC-3-29e29097123bbe5a3d876e9a5b13157c1d3f710273047c44f7fdd07ef4eb0811.jpg"})